NIAID

Category

University of Cincinnati Selected by NIAID as Phase III Clinical Trial Site for mRNA-1273 COVID-19 Vaccine

The University of Cincinnati (UC) has been selected by the National Institute of Allergy and Infectious Diseases (NIAID) as a clinical investigational site for the pivotal Phase III clinical trial evaluating the effectiveness of Moderna’s mRNA-1273 COVID-19...

UT Austin & VIB-led Team Identify that Special Antibody from Llama can Neutralize SARS-CoV-2 in a Cell Culture

A team of researchers out of University of Texas VIB-UGent Center for Medical Biotechnology and the National Institutes of Health (NIH) recently published a peer-reviewed study revealing that the blood from a South American camelid, the llama, could represent the path...

UC Irvine Initiates Participation in Worldwide NIAID-Sponsored Adaptive COVID-19 Clinical Trial Assessing Remdesivir (Gilead)

University of California, Irvine (UCI) joins other pathbreaking major academic centers serving as clinical investigative sites nationwide to test Gilead’s remdesivir, the novel antiviral drug developed as a treatment for the Ebola and Marburg virus. With UCI’s...

NIAID Recent Advances in Addressing TB

A new “Perspective” in the Journal of Infectious Diseases by NIAID Director Anthony S. Fauci, MD, and other institute officials summarizes recent progress in improved TB diagnostics, therapeutic regimens and prevention approaches that made 2019 a “banner year” for TB...

NIAID Sponsors Phase I Clinical Trial of mAb CIS43LS Targeting Malaria

The National Institute of Allergy and Infectious Diseases (NIAID) has developed a monoclonal antibody (mAb) called mAb CIS43LS targeting malaria. They are now enrolling healthy adult volunteers in a Phase I clinical trial testing the safety and effectiveness of the...

Pin It on Pinterest